Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation

This study has been completed.
Information provided by (Responsible Party):
Katherina Farr, University of Aarhus Identifier:
First received: December 6, 2012
Last updated: July 6, 2015
Last verified: July 2015
Overall objective of the study is to compare the use of SPECT in radiotherapy treatment planning with standard CT-based radiotherapy for stage I-III non-small-cell lung cancer patients

Condition Intervention
Non-small-cell Lung Cancer
Radiation Pneumonitis
Other: SPECT-based treatment plan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Role of SPECT in Radiotherapy Treatment Planning and Toxicity Evaluation for the Patients With Stage I-III NSCLC: a Randomized Phase II Trial

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Grade 2 radiation pneumonitis [ Time Frame: measured 0-12 months after completed radiotherapy ]

    The primary endpoint is grade 2 pneumonitis, defined according to the NCI Common Toxicity Criteria for Adverse Events (CTC) version 4.0.

    Estimation of the occurrence of pulmonary tissue effects:

    Number of patients developing pulmonary toxicity over grade 2 in both treatment arms according to the Common Terminology Criteria for Adverse Events CTC v. 4.0 and measured serially from 0 to 12 months after radiotherapy, as well as according to the SOMA-LENT scale measured serially from 0 to 12 months after radiotherapy

Secondary Outcome Measures:
  • quality of life [ Time Frame: 0-12 months after radiotherapy ]
    Change in quality of life according to the standard quality of life questionnaires

  • Mean lung dose (MLD) and V5-50(volume of the lung receiving 5-50 Gy or more) [ Time Frame: 12 months after radiotherapy ]
    Estimation of conventional (from CT alone) and functional (from SPECT)dose-volume parameters (MLD and V5-50) and their correlation with pulmonary toxicity will be done.

  • Progression-free survival [ Time Frame: at 12 months after radiotherapy ]
    Proportion of patients alive with no evidence of disease as per the RECIST criteria in the SPECT arm compared to CT arm

Enrollment: 71
Study Start Date: June 2012
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Arm 1
SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
Other: SPECT-based treatment plan

SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.

The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated

Other Name: Single Photon Emission Computed Tomography

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage I-III non-small cell lung cancer, histologically verified
  • Referred for definitive radiotherapy to the Department of Oncology, Aarhus University Hospital
  • Meet the criteria for curatively intended radiotherapy described in details in the national guidelines
  • Concurrent chemotherapy is accepted
  • Adults over 18, that have given oral and written informed consent before patient registration
  • The patients can only be randomized in this trial once

Exclusion Criteria:

  • other uncontrolled malignancies
  • human albumin allergy
  • any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01745484

Department of Oncology, Aarhus University Hospital
Aarhus, Denmark, DK-8000
Sponsors and Collaborators
University of Aarhus
Principal Investigator: Katherina Farr, MD Department of Oncology, Aarhus University Hospital
  More Information

Responsible Party: Katherina Farr, Principle Investigator, University of Aarhus Identifier: NCT01745484     History of Changes
Other Study ID Numbers: KFE-1203
Study First Received: December 6, 2012
Last Updated: July 6, 2015

Keywords provided by University of Aarhus:
Non-small-cell lung cancer
Definitive Radiotherapy
Radiation pneumonitis
Randomized study

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Radiation Pneumonitis
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Diseases, Interstitial
Lung Injury
Radiation Injuries
Wounds and Injuries
Respiratory Tract Infections processed this record on April 28, 2017